Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

4940 - HER2 amplification is associated with higher tumor mutation burden in breast cancer

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Topics

Targeted Therapy

Tumour Site

Breast Cancer

Presenters

Yongmei Yin

Citation

Annals of Oncology (2018) 29 (suppl_8): viii14-viii57. 10.1093/annonc/mdy269

Authors

Y. Yin1, W. Li1, X. Huang1, H. Wu1, Y. Zhang2, S. Cai2, S. Zhou3

Author affiliations

  • 1 Department Of Oncology, Jiangsu Province Hospital, 210029 - Nanjing/CN
  • 2 The Medical Department, 3D medicines Inc., 201114 - Shanghai/CN
  • 3 Department Of Breast Surgery, the Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, 650000 - Kunming/CN
More

Resources

Abstract 4940

Background

ErbB family consists of four transmembrane proteins (ErbB1/EGFR/HER1, ErbB2/HER2, ErbB3/HER3 and ErbB4/HER4) and plays a prominent role in the process of cell growth. Previous studies suggested that EGFR gene driven non-small-cell-cancer exhibited a suppressive immunity with lower tumor mutation burden (TMB) level. HER2 gene amplification (HER2+) is a well-known poor prognosis predictor in breast cancer and anti-HER2 target therapy has significantly improved the clinical prognosis of HER2+ patients. However, the association between HER2 gene alteration and TMB in breast cancer is still unclear.

Methods

Whole-exome sequencing data and clinical data of 366 breast tumors from The Cancer Genome Altas (TCGA) and next generation sequencing (NGS) data of 335 breast tumors from clinical dataset were analyzed to explore the association between HER2 gene alteration and TMB. TMB was defined as total number of somatic non-synonymous mutations in coding region.

Results

20.5% (75/366) of breast tumors in TCGA cohort and 20.3% (68/335) in clinical cohort harbored HER2 amplification. HER2 amplification was significantly associated with higher TMB in both TCGA cohort (P = 0.010) and clinical cohort (P = 0.008). HER2 somatic alteration occurred in 3.7% (12/366) of breast tumors in TCGA cohort and 7.2% (24/335) in clinical cohort. HER2 somatic alteration was also associated with higher TMB level in TCGA cohort (P = 0.016), but no association was observed in clinical cohort (P = 0.339). In addition, hormonal receptor (HR) + HER2- breast tumors exhibited the lowest TMB level compared with HR+ HER2 + (P = 0.001), HR-HER2 + (P = 0.052) and triple negative breast cancer (P = 0.000). Patients with low TMB level also tended to have a better overall survival than patients with higher TMB level (median, 216.6 vs. 112.0 months; HR, 0.572; 95% CI 0.31-3.05; P = 0.067).

Conclusions

HER2 amplification is associated with higher TMB in breast cancer. These findings may assist the selection of breast cancer patients likely to benefit from immunotherapy.

Clinical trial identification

Legal entity responsible for the study

Yongmei Yin and Shaoqiang Zhou.

Funding

National Natural Science Foundation of China.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.